Berenberg Madrid Seminar
Mediathek Category
Mediathek Preview File
Mediathek Download
Mediathek Date
Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the largest U.S. provider of healthcare performance improvement services. This recognition reflects Fresenius Kabi’s commitment to collaboration and innovation to enhance quality of care and patient safety.
This is Fresenius Kabi’s second time being named Vizient’s Supplier Partner of the Year.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN, SINGAPORE OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan, Singapore or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SINGAPORE OR JAPAN.
Fresenius has successfully placed a €500 million bond with a 7-year maturity and an annual coupon of 5.125%.
The transaction follows the successful debut issuance of Fresenius in the Swiss bond market with a CHF275 million bond with a 5-year maturity and an annual coupon of 2.96%.
The proceeds of both transactions will be used for general corporate purposes, including the refinancing of existing financial liabilities. The bonds were drawn under the Fresenius Debt Issuance Program and issued by Fresenius SE & Co. KGaA.
For the €500 million bond, Fresenius has applied to the Luxembourg Stock Exchange to admit the bond to trading on its regulated market. The envisaged settlement date is October 5, 2023. For the CHF275 million bond, application will be made for the listing of the bond on the SIX Swiss Exchange. The envisaged settlement date is October 18, 2023.
Fresenius is a regular issuer in the Euro bond market, as well as in the Schuldschein market. With its inaugural CHF bond, the company seeks to further diversify its funding sources, as well as to broaden its investor universe. Access to different bond markets and a diversification of financing instruments are important components of Fresenius’ financing strategy.
Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA. Deleveraging and a strong balance sheet focus combined with clear capital allocation priorities are key aspects to deliver on #FutureFresenius.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, Singapore or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Singapore or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Singapore. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Singapore. There will be no public offer of the securities in the United States.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
Additional note regarding the Euro bond issue:
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus, as supplemented, in combination with the relevant final terms relating to such securities, to be issued by the company in connection with the offering of such securities. The applicable final terms for such securities, when published, will be available on the website of the Luxembourg Stock Exchange (www.LuxSE.com) together with the prospectus and any supplement thereto. Copies of the prospectus are also available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area ("EEA") will be made pursuant to the prospectus and any supplement thereto prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the “Prospectus Regulation”) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
Fresenius Kabi and its license partner Formycon announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for FYB202, an Ustekinumab biosimilar candidate. FYB202 references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
Fresenius Kabi is the commercialization partner. The acceptance of the MAA for review marks another milestone in the company’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
* Stelara® is a registered trademark of Johnson & Johnson
Fresenius Kabi and its license partner Formycon announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for FYB202, an Ustekinumab biosimilar candidate. FYB202 references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
Fresenius Kabi is the commercialization partner. The acceptance of the MAA for review marks another milestone in the company’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
* Stelara® is a registered trademark of Johnson & Johnson
Fresenius makes available €500.000 for immediate release to the German Red Cross (Deutsches Rotes Kreuz e.V.) as assistance for disaster relief efforts to people affected by the recent earthquake in Morocco and the flooding in Libya. This cash donation will support direct disaster relief efforts on site. In addition, Fresenius remains committed to providing assistance with much needed medical products from its own product portfolio in crisis situations.
Fresenius makes available €500.000 for immediate release to the German Red Cross (Deutsches Rotes Kreuz e.V.) as assistance for disaster relief efforts to people affected by the recent earthquake in Morocco and the flooding in Libya. This cash donation will support direct disaster relief efforts on site. In addition, Fresenius remains committed to providing assistance with much needed medical products from its own product portfolio in crisis situations.
Citi's European Healthcare Bus Tour
Mediathek Category
Mediathek Preview File
Mediathek Download
Mediathek Date